• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型心肌病高危患者植入式心脏除颤器放电的决定因素。

Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.

作者信息

Woo Anna, Monakier Daniel, Harris Louise, Hill Ann, Shah Prasad, Wigle E Douglas, Rakowski Harry, Rozenblyum Evelyn, Cameron Douglas A

机构信息

Division of Cardiology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

Heart. 2007 Sep;93(9):1044-5. doi: 10.1136/hrt.2006.090290.

DOI:10.1136/hrt.2006.090290
PMID:17699173
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1955000/
Abstract

OBJECTIVES

To identify the determinants of appropriate and inappropriate implantable cardioverter-defibrillator (ICD) discharges in patients with hypertrophic cardiomyopathy (HCM).

DESIGN

Retrospective cohort study.

SETTING

ICD clinic at an academic hospital.

PATIENTS

61 patients with HCM who received ICDs for the primary or secondary prevention of sudden cardiac death (SCD).

OUTCOME MEASURES

(a) Analysis of appropriate and inappropriate ICD discharges; (b) predictors of ICD discharges.

RESULTS

Mean (SD) age at ICD insertion was 46 (18) years (range 10-79). Follow-up time was 40 (27) months (range 7-151). Eight patients experienced an appropriate discharge, occurring 24.5 (13.6) months after ICD insertion. Appropriate ICD intervention was more common in the secondary (36%) than the primary (8%) prevention group (p = 0.02). Inappropriate ICD discharges occurred in 20 (33%) patients. Multivariate Cox regression analysis identified two significant predictors of inappropriate ICD discharges: (a) age <30 years at the time of ICD insertion (hazard ratio (HR) = 3.0 (95% CI 1.1 to 8.0; p = 0.03) and (b) history of atrial fibrillation (HR = 3.1 (95% CI 1.2 to 8.1; p = 0.02).

CONCLUSIONS

ICDs are effective in the prevention of SCD in HCM. However, there is a high incidence of inappropriate ICD discharges.

摘要

目的

确定肥厚型心肌病(HCM)患者中合适及不合适的植入式心律转复除颤器(ICD)放电的决定因素。

设计

回顾性队列研究。

地点

一所学术医院的ICD诊所。

患者

61例因心脏性猝死(SCD)的一级或二级预防而接受ICD植入的HCM患者。

观察指标

(a)合适及不合适的ICD放电分析;(b)ICD放电的预测因素。

结果

ICD植入时的平均(标准差)年龄为46(18)岁(范围10 - 79岁)。随访时间为40(27)个月(范围7 - 151个月)。8例患者经历了合适的放电,发生在ICD植入后24.5(13.6)个月。合适的ICD干预在二级预防组(36%)比一级预防组(8%)更常见(p = 0.02)。20例(33%)患者发生了不合适的ICD放电。多因素Cox回归分析确定了不合适ICD放电的两个显著预测因素:(a)ICD植入时年龄<30岁(风险比(HR)= 3.0(95%可信区间1.1至8.0;p = 0.03))和(b)心房颤动病史(HR = 3.1(95%可信区间1.2至8.1;p = 0.02))。

结论

ICD对预防HCM患者的SCD有效。然而,不合适的ICD放电发生率很高。

相似文献

1
Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.肥厚型心肌病高危患者植入式心脏除颤器放电的决定因素。
Heart. 2007 Sep;93(9):1044-5. doi: 10.1136/hrt.2006.090290.
2
Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.肥厚型心肌病患者的植入式心脏复律除颤器:长期随访中的疗效和治疗并发症。
J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):883-9. doi: 10.1111/j.1540-8167.2009.01716.x. Epub 2010 Feb 1.
3
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.植入式心脏复律除颤器在肥厚型心肌病中的应用:患者结局、恰当和不恰当干预的发生率以及并发症。
Am Heart J. 2013 Sep;166(3):496-502. doi: 10.1016/j.ahj.2013.06.009. Epub 2013 Jul 16.
4
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.植入式心律转复除颤器预防肥厚型心肌病儿童和青少年心源性猝死。
J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35. doi: 10.1016/j.jacc.2013.01.037.
5
Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.肥厚型心肌病患者植入式心脏复律除颤器——困境与难题
Kardiol Pol. 2005 Oct;63(4):391-7; discussion 398.
6
Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者的器械并发症及不适当的植入式心脏复律除颤器电击
Heart. 2009 May;95(9):709-14. doi: 10.1136/hrt.2008.150656. Epub 2009 Mar 11.
7
[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].[植入式心脏复律除颤器与肥厚型心肌病。三个中心的经验]
Rev Esp Cardiol. 2006 Jun;59(6):537-44.
8
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.植入式心脏复律除颤器与肥厚型心肌病心脏性猝死的预防
JAMA. 2007 Jul 25;298(4):405-12. doi: 10.1001/jama.298.4.405.
9
Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.植入式心脏复律除颤器治疗对肥厚型心肌病酒精间隔消融术后猝死的一级预防
J Am Coll Cardiol. 2008 Nov 18;52(21):1718-23. doi: 10.1016/j.jacc.2008.07.061.
10
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.植入式心脏复律除颤器对肥厚型心肌病患者预防猝死的疗效。
N Engl J Med. 2000 Feb 10;342(6):365-73. doi: 10.1056/NEJM200002103420601.

引用本文的文献

1
Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy.肥厚型心肌病患者植入式心律转复除颤器的使用情况及预后的全球和时间趋势
Circ Arrhythm Electrophysiol. 2025 Feb;18(2):e013479. doi: 10.1161/CIRCEP.124.013479. Epub 2025 Feb 3.
2
Factors associated with implantable cardioverter-defibrillator shocks in patients suffering from non-ischemic cardiomyopathy.非缺血性心肌病患者植入式心脏复律除颤器电击相关因素。
ARYA Atheroscler. 2022 May;18(3):1-9. doi: 10.48305/arya.2022.24342.
3
The Arrhythmic Phenotype in Cardiomyopathy.心肌病的心律失常表型。
Heart Fail Clin. 2022 Jan;18(1):101-113. doi: 10.1016/j.hfc.2021.07.011. Epub 2021 Oct 22.
4
Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.美国心脏病学会/美国心脏协会优化的肥厚型心肌病高危患者心源性猝死预防策略。
JAMA Cardiol. 2019 Jul 1;4(7):644-657. doi: 10.1001/jamacardio.2019.1391.
5
Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.肥厚型心肌病的植入式心脏复律除颤器治疗:结局与并发症的最新系统评价和荟萃分析
Ann Cardiothorac Surg. 2017 Jul;6(4):298-306. doi: 10.21037/acs.2017.07.05.
6
Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.全球纵向应变和左心房容积指数可改善肥厚型心肌病患者植入式心脏复律除颤器治疗的预测。
Int J Cardiovasc Imaging. 2014 Mar;30(3):549-58. doi: 10.1007/s10554-014-0378-z. Epub 2014 Feb 6.
7
A primer on arrhythmias in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者心律失常概述。
Curr Cardiol Rep. 2012 Oct;14(5):552-62. doi: 10.1007/s11886-012-0297-3.
8
Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events.肥厚型心肌病确诊儿童及青少年的长期随访:心律失常不良事件的危险因素
Pediatr Cardiol. 2011 Dec;32(8):1096-105. doi: 10.1007/s00246-011-9967-y. Epub 2011 Apr 13.
9
Sudden death in hypertrophic cardiomyopathy.肥厚型心肌病中的猝死。
J Cardiovasc Transl Res. 2009 Dec;2(4):368-80. doi: 10.1007/s12265-009-9147-0. Epub 2009 Nov 13.
10
Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.肌丝钙敏化导致小鼠易患心律失常。
J Clin Invest. 2008 Dec;118(12):3893-903. doi: 10.1172/JCI36642. Epub 2008 Nov 20.

本文引用的文献

1
High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.植入式心脏复律除颤器在儿童和青少年中适当和不适当治疗的高发生率。
Pacing Clin Electrophysiol. 2004 Jul;27(7):924-32. doi: 10.1111/j.1540-8159.2004.00560.x.
2
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.美国心脏病学会/欧洲心脏病学会关于肥厚型心肌病的临床专家共识文件。美国心脏病学会基金会临床专家共识文件特别工作组及欧洲心脏病学会实践指南委员会的报告。
J Am Coll Cardiol. 2003 Nov 5;42(9):1687-713. doi: 10.1016/s0735-1097(03)00941-0.
3
Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.植入式心脏复律除颤器治疗肥厚型心肌病心脏性猝死一级和二级预防的疗效
Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96. doi: 10.1046/j.1460-9592.2003.00285.x.
4
Is inappropriate implantable defibrillator shock therapy predictable?
J Interv Card Electrophysiol. 2003 Jun;8(3):215-20. doi: 10.1023/a:1023973306742.
5
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.植入式心脏复律除颤器对肥厚型心肌病患者预防猝死的疗效。
N Engl J Med. 2000 Feb 10;342(6):365-73. doi: 10.1056/NEJM200002103420601.